SynthesisBMC pregnancy and childbirth2025
Adverse effects of dipyrone (Metamizole) use during pregnancy on offspring health: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population-Based Cohort Study.Clinical pharmacology and therapeutics · 2026Article
- Dipyrone use in Brazil: clinical conditions, sociodemographic characteristics, population attitudes and perceptions.Cadernos de saude publica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis and systematic review aimed to review the health outcomes of offspring following dipyrone use during pregnancy.
methodsA systematic literature search was conducted in MEDLINE, Embase, and the Cochrane Library to identify clinical trials or observational studies investigating women who used dipyrone during pregnancy (up to 16 August 2024). The data was analyzed using odds ratios (ORs) with inverse variance and Bayesian random effects models.
resultsSix case-control studies and four prospective cohort studies met the inclusion criteria. No association was found with birth defects (OR 1.27, 95% CI 0.83–1.77; I2 = 39.94%; 3 cohorts and 1 case-control), major anomalies (OR 1.06, 95% CI 0.47–2.37; I2 = 14.35%; 2 cohorts), infant leukemia (OR 1.25, 95% CI 0.86–2.22; I2 = 72.82%; 2 case-controls), gestational loss (OR 0.80, 95% CI 0.57–1.13; 3 cohorts), prematurity (OR 0.99, 95% CI 0.80–1.21; I2 = 0%; 3 cohorts), low birth weight, constriction of the ductus arteriosus, or renal and cardiac disorders. However, all analyses were of low or very low certainty.
conclusionNo association was found between maternal use of dipyrone in the investigated outcomes, although these conclusions are limited by the quality of the included studies, sample size, and overall evidence. Further research with a better assessment of exposure is required to exclude risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.